Clinical trialNCT03418038RecruitingPhase 2Interventional

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

SponsorMayo ClinicEnrollment80Chronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined SignificanceHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin LymphomaRecurrent Lymphoma+2 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells. Arms A, B, C, and D are closed to enrollment.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Thomas E Witzig, M.D.
Mayo Clinic
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Health Systems-Mankato
Mankato, Minnesota, United States
Stephan D. Thome, M.D.
Not, yet, recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Thomas E. Witzig, M.D.
Recruiting
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin, United States
Eyad S. Al-Hattab, M.D.
Not, yet, recruiting
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, United States
Active, not recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Cisplatin →Cytarabine →Decitabine →Dexamethasone →Etoposide →Gemcitabine →IfosfamideOxaliplatin →Rituximab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Mar 2018
Primary completion: 22 Feb 2031
Completion: 2 Nov 2033
Last update posted: 16 Apr 2026
Registered enrollment: 80
Registry id: NCT03418038

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.